Verily

Name: Verily
Brand: Verily

Leader

We are a data platform and technology company purpose-built to power AI-enabled precision health.

Est 2015|Valuation $1.6B|58 Ref Customers

LinkedIn 182K|Web traffic 63K|FTEs 1,182|HQ Dallas, Texas, US

Published Oct 15, 2026

01Common complaints

- If an organization requires an enterprise-grade CTMS with extensive feature breadth and long-established adoption for complex, multi-site, global clinical trial operations, alternative incumbent CTMS vendors (Medidata, Veeva, Advarra) may be more appropriate. - If an organization requires transparent, publicly available pricing and a fully standardized procurement package without vendor engagement, the vendor's largely quote-based commercial model for enterprise modules may slow procurement. - If extensive, independent validation of AI capabilities and benchmark-style performance comparisons are a primary procurement requirement, public independent benchmarks for the full platform were limited in accessible sources. - If the dominant requirement is a general-purpose lakehouse/warehouse with broad enterprise adoption and extensive data engineering ecosystem support, general-purpose platforms (Databricks, Snowflake, Microsoft Fabric) may be better suited. - If organizational stability and roadmap continuity are top procurement concerns, buyers should evaluate reported organizational changes and confirm long-term support commitments. - Current limitations acknowledged in accessible sources - Vendor materials emphasize capabilities; explicit vendor-published limitations were not prominent in the accessible materials. - Features on the roadmap (not yet available) - Roadmap details were not systematically documented in accessible public sources. - Scale limitations - No explicit scale ceilings were documented in accessible sources. - Security or compliance gaps - While SOC 2 Type II and ISO 27001 are shown on the vendor's Security & Trust page, documentation for other commonly requested enterprise needs (ISO 27017/27018, data residency options, detailed SSO/SCIM integration documentation) was not found in accessible sources. - Technical debt or architectural limitations mentioned in reviews - Not found in accessible public sources. - API limitations or integration constraints - Not found in accessible public sources.

02Why they buy

- Competitive advantages validated by customer feedback (not just vendor claims) - Limited: publicly accessible, third-party product feedback for Pre is sparse. The clearest verified signals were community comments indicating potential limitations for Viewpoint rather than strong, validated differentiators. - Unique features and capabilities described by the vendor (vendor-framed; requires validation) - Pre Exchange described as a dataset discovery and exchange capability integrated with the vendor's platform and analytics modules. - Vendor describes Pre as a platform designed to support healthcare-specific AI workflows and orchestration for health data. - Differentiation from competitors based on reviews - Not enough public product reviews were accessible to conclusively establish differentiation from peer sentiment. - Value propositions with evidence from case studies - Vendor-published Viewpoint CTMS case studies claim operational and financial improvements; these are vendor-authored and should be validated by reference checks and quantified ROI analysis. - Areas where competitors clearly have advantages - Medidata, Veeva, and Advarra: deeper, established CTMS ecosystems and stronger enterprise adoption in many segments. - Databricks, Snowflake, Microsoft Fabric: larger general-purpose data platform ecosystems and mature enterprise data engineering tooling.

03Field reports

Note: Mainstream B2B review platforms (G2/TrustRadius/Gartner Peer Insights) did not show easily accessible product-specific review pages for Verily Pre or Verily Viewpoint during this research. - Direct quotes (community / social) - Reddit (biotech career discussion; commentary about company operations rather than product quality) - Critical comment (anecdotal): "...i wouldn’t personally work for verily. i’ve worked with them before on a couple projects and it just felt chaotic." - Reddit (clinical research product sentiment; Viewpoint CTMS) - Critical comment: "We did demos of it and in my opinion it’s just not as robust as others out there." - Mixed/limiting comment: "It will work for a single site just looking to be better organized but it’s not a comprehensive CTMS solution." - Glassdoor (employment sentiment; proxy for operational/support culture rather than product outcomes) - Glassdoor aggregate rating snapshot (caution: not a product review): Verily showed a below-average company rating on Glassdoor based on several hundred company reviews (as shown on Glassdoor at the time of research). - Attempts to locate Gartner Peer Insights / G2 / TrustRadius product reviews - Gartner Peer Insights - Attempted; a product-specific Verily page with reviews was not surfaced in accessible results. - G2 - Attempted; no clear Verily Pre / Viewpoint review page found. - TrustRadius - Attempted; no clear Verily Pre / Viewpoint review page found. - Common criticisms and complaints (from available sources) - Viewpoint Site CTMS was described by some clinical research professionals in community sources as having less feature depth than some established CTMS alternatives; comments suggested it may be more suitable for single-site or less complex workflows than for comprehensive, enterprise CTMS needs. - Broader company-level concerns (not product-specific) - Public reports of layoffs and leadership turnover were noted in coverage and can increase perceived risk regarding long-term roadmap continuity and support investment; these are indirect signals rather than product evaluations. - Why customers chose this product over alternatives (evidence limitations) - Vendor case studies emphasize usability and finance workflow improvements for research sites (e.g., Bon Secours Mercy Health). These are vendor-authored and are not independently verified in this report. - Why some customers left for competitors (churn reasons) - No direct churn narratives were found in accessible sources. - Specific outcomes customers achieved (with metrics when available) - Vendor-authored case studies report operational improvements, but these materials do not consistently provide independently verifiable metrics or methodology. - Deal-breakers and reasons customers didn't purchase - From community comments: perceived lack of breadth or depth in CTMS feature sets compared with established CTMS vendors was cited as a reason to choose alternatives for more complex needs.

Vendor-published case studies

- Bon Secours Mercy Health (Viewpoint Site CTMS) - Vendor materials describe improvements in research finance processes attributed to Viewpoint Site CTMS. - Critical evaluation - This case study is vendor-authored; metrics, baseline definitions, and methodology are not independently audited in the accessible material. - Recommended follow-ups for procurement and validation - Request before/after financial and operational metrics (e.g., billing cycle measures, missed billing items, study startup time) - Ask for implementation duration, staffing, and total services costs - Request reference calls with the customer

Platform consolidation claims (Pre used across solutions)

The vendor states the Pre platform serves as the underlying platform for multiple Verily solutions.
Critical evaluation
- Architectural consolidation can reduce duplication, but platform use across multiple solutions does not, by itself, demonstrate superior capabilities versus specialist platforms (e.g., Databricks for lakehouse engineering; Medidata/Veeva for clinical operations).

04Best fit

Ideal Customer Profile

- Company sizes - Best-fit appears to be - Mid-market to enterprise health systems and research organizations - Life sciences organizations pursuing AI, real-world data initiatives, and multimodal data curation - Public-sector and federal buyers (given procurement signals such as awardable status and FedRAMP-type controls for parts of the platform) - Industries and verticals where adoption is most likely - Clinical research sites and health systems (vendor highlights include Bon Secours Mercy Health for CTMS use) - Public health monitoring and surveillance programs (e.g., wastewater/pathogen trend monitoring) - Roles and personas - Decision makers - Chief data and analytics leaders in health systems - Clinical research operations leadership - Clinical informatics and digital transformation leaders - Public health program leadership - Federal procurement and security stakeholders - End users - Data scientists and biostatisticians - Clinical research coordinators and finance teams (Viewpoint CTMS) - Researchers needing dataset discovery and analysis (Exchange/Workbench) - Pain points and challenges the product addresses - Harmonizing and curating multimodal health data for AI and research - Discovering and acquiring biomedical datasets via a discovery and exchange capability - Reducing operational friction in research site trial management and protocol digitization - Qualification criteria: what makes a fit - The organization manages multimodal data (EHR, imaging, unstructured documents) and has resources to invest in governance and data engineering. - The organization prefers procurement pathways aligned with FedRAMP-type controls for parts of the platform. - The organization prefers an integrated platform approach rather than assembling multiple point solutions. - Deal disqualifiers: what makes a poor fit - The organization requires extensive third-party validation, a large body of peer product reviews, and long-established market validation before purchase. - The organization needs a fully mature, enterprise-grade CTMS with deep sponsor- or CRO-centric workflows comparable to incumbent leaders and cannot tolerate perceived feature gaps.

05The pitch

What the product does (core value proposition in objective terms)

- Verily is described by the vendor as a healthcare-focused AI company that offers a platform and associated applications intended to help health systems, life sciences organizations, researchers, and public-sector stakeholders organize, govern, analyze, and operationalize multimodal health data for research and care. This vendor positioning is reported here as vendor-framed and is not independently validated in this report. - The vendor markets a platform called Verily Pre and solution lines including Workbench (analysis), Exchange (data discovery/marketplace), Refinery (data harmonization/curation), Viewpoint (clinical research operations / site CTMS + digital protocols), Verily Me (consumer app), and Sightline (population-level disease monitoring).

Target market and market positioning

- Stated target segments (based on the vendor's own positioning) - Life sciences / clinical research stakeholders - Health systems and researchers - Public health / health security (e.g., wastewater and pathogen trend monitoring) - U.S. consumers (via Verily Me) - Positioning theme - Vendor materials describe a healthcare-focused AI platform approach with modular solution components built on the platform.

Get a comprehensive analysis of Verily including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →